Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Alloy vs Vea Health

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.4

Alloy

Best for women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory
★★★3.7

Starting at $80/mo

Brand WegovyBrand ZepboundCompounded SemaglutideCompounded Tirzepatide
Visit Alloy
5.8

Vea Health

Best for Men interested in a longevity + performance + weight-loss bundled telehealth platform who are comfortable with limited pricing transparency upfront and a men's-health-first brand positioning, and who want to read the FDA compounded-medication disclaimer before purchasing.
★★☆☆2.9
Compounded Semaglutide (oral + injection)Compounded Tirzepatide (oral + injection)Telehealth-onlyAll 50 states (per homepage claim)
Visit Vea Health

Side-by-Side Comparison

FeatureAlloyVea Health
Overall Score7.4/105.8/10
Starting Price$80/mo
Editorial Rating3.7 ★ /52.9 ★ /5
Features8 features6 features
States Available00
Compounded✓ Yes
Brand Name✓ Yes
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

Alloy

Pros

  • Broadest GLP-1 formulary in our catalog: brand Wegovy + brand Zepbound + oral Wegovy + compounded semaglutide + compounded tirzepatide + compounded liraglutide
  • All consulting doctors are certified by The Menopause Society — only ~1,000 such certified practitioners exist among ~20,000 OB-GYNs in the US
  • Brand-name Wegovy starting at $199/mo and compounded liraglutide starting at $80/mo cover both ends of the price/access spectrum
  • STARTGLP1 promo code knocks $50 off the first month per the public site

Cons

  • Not available in Louisiana or Mississippi (verified) — readers in those two states should be routed elsewhere
  • Initial consultation is $49 and is separate from medication cost — readers should know there's a non-refundable upfront fee
  • Menopause-specialty framing — best fit for women in menopause/perimenopause, not the right product for men or younger women whose primary need is weight loss

Vea Health

Pros

  • Verbatim FDA compounded-medication disclaimer published — unusual transparency
  • Oral AND injection protocols offered for both semaglutide and tirzepatide
  • Claims 50-state coverage via clinician network
  • Brand positioning is clearly differentiated (longevity + men's health + performance) vs generic DTC GLP-1

Cons

  • Pricing NOT disclosed on the public homepage — gated behind sign-up flow
  • Pharmacy partner NOT named — only 'U.S.-based pharmacy' framing
  • LegitScript certification status NOT visible on homepage
  • Named medical director NOT disclosed
  • 503A vs 503B designation NOT specified
  • Corporate legal entity (LLC/Inc/PC) NOT disclosed
  • Men's-health-first positioning may not align with women's weight-loss audience

Our Verdict

Winner: AlloyScore: 7.4/10

Alloy edges out Vea Health with a higher overall score of 7.4/10 and is particularly strong for women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory. Vea Health remains a solid alternative, especially if you're looking for Men interested in a longevity + performance + weight-loss bundled telehealth platform who are comfortable with limited pricing transparency upfront and a men's-health-first brand positioning, and who want to read the FDA compounded-medication disclaimer before purchasing..

Glossary references

Key terms in this article, linked to their canonical definitions.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.